Skip to main content

Inside the booming weight loss drug market

Known as GLP-1 agonists, new drugs could change how doctors treat obesity and, possibly, how the condition is more broadly understood. They could also raise healthcare spending substantially, posing a problem for insurers looking to control costs.

included in this trendline
  • Wegovy approval for the heart broadens obesity drug use
  • Medicare cracks open coverage for Novo obesity drug
  • Novo pill could be company’s next entrant in obesity drug race
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.